Literature DB >> 24842353

Hand, foot and scrotal blisters in a patient with cancer receiving oral chemotherapy.

Jose Rodolfo Guerra1, Ana M Suelves1, Archie Bella1, Delatre Lolo1.   

Abstract

Tyrosine kinase inhibitors are novel antineoplastic drugs that make use of the molecular abnormalities that have been discovered in certain types of tumours. These agents are associated with important dermatological side effects. This case report discusses an atypical presentation of the hand-foot syndrome in one patient treated with sorafenib. A 78-year-old man, recently started on sorafenib for the treatment of hepatocarcinoma with lung metastasis, presented to the emergency room with painful blistering lesions on the palms, soles and scrotum for 1 week. A punch biopsy was performed and sorafenib was withheld. Direct immunofluorescence study was negative for an autoimmune blistering disorder and histopathology stains did not show any microorganisms. A diagnosis of hand-foot syndrome was made. After 2 weeks, the patient showed marked improvement and the plan was to restart sorafenib at a lower dosage. 2014 BMJ Publishing Group Ltd.

Entities:  

Mesh:

Substances:

Year:  2014        PMID: 24842353      PMCID: PMC4039891          DOI: 10.1136/bcr-2013-202822

Source DB:  PubMed          Journal:  BMJ Case Rep        ISSN: 1757-790X


  10 in total

1.  Acral erythrodysesthesia syndrome caused by intravenous infusion of docetaxel in breast cancer.

Authors:  Dorothee Eich; Karin Scharffetter-Kochanek; Hans Theodor Eich; Iliana Tantcheva-Poor; Thomas Krieg
Journal:  Am J Clin Oncol       Date:  2002-12       Impact factor: 2.339

Review 2.  Cutaneous side-effects of kinase inhibitors and blocking antibodies.

Authors:  Caroline Robert; Jean-Charles Soria; Alain Spatz; Axel Le Cesne; David Malka; Patricia Pautier; Janine Wechsler; Catherine Lhomme; Bernard Escudier; Valérie Boige; Jean-Pierre Armand; Thierry Le Chevalier
Journal:  Lancet Oncol       Date:  2005-07       Impact factor: 41.316

3.  Hand-foot syndrome following prolonged infusion of high doses of vinorelbine.

Authors:  P M Hoff; V Valero; N Ibrahim; J Willey; G N Hortobagyi
Journal:  Cancer       Date:  1998-03-01       Impact factor: 6.860

4.  Erythematous eruption of the palms and soles associated with mitotane therapy.

Authors:  R L Zuehlke
Journal:  Dermatologica       Date:  1974

5.  Probable cytarabine-induced acral erythema: report of 2 pediatric cases.

Authors:  Serap Ozmen; Mahmut Dogru; Ceyhun Bozkurt; Ayse Ceyda Kocaoglu
Journal:  J Pediatr Hematol Oncol       Date:  2013-01       Impact factor: 1.289

6.  Palmar-plantar erythrodysesthesia associated with scrotal and penile involvement with capecitabine.

Authors:  Christy M Sapp; Philip DeSimone
Journal:  Clin Colorectal Cancer       Date:  2007-01       Impact factor: 4.481

Review 7.  Hand-foot syndrome (hand-foot skin reaction, palmar-plantar erythrodysesthesia): focus on sorafenib and sunitinib.

Authors:  Adam D Lipworth; Caroline Robert; Andrew X Zhu
Journal:  Oncology       Date:  2009-11-16       Impact factor: 2.935

Review 8.  Evolving strategies for the management of hand-foot skin reaction associated with the multitargeted kinase inhibitors sorafenib and sunitinib.

Authors:  Mario E Lacouture; Shenhong Wu; Caroline Robert; Michael B Atkins; Heidi H Kong; Joan Guitart; Claus Garbe; Axel Hauschild; Igor Puzanov; Doru T Alexandrescu; Roger T Anderson; Laura Wood; Janice P Dutcher
Journal:  Oncologist       Date:  2008-09-08

9.  Hand foot skin reaction in cancer patients treated with the multikinase inhibitors sorafenib and sunitinib.

Authors:  M E Lacouture; L M Reilly; P Gerami; J Guitart
Journal:  Ann Oncol       Date:  2008-06-10       Impact factor: 32.976

10.  Palmar-plantar erythrodysesthesia associated with chemotherapy and its treatment.

Authors:  Katherina Podlekareva Farr; Akmal Safwat
Journal:  Case Rep Oncol       Date:  2011-04-11
  10 in total
  1 in total

1.  Cutaneous adverse effects associated with the tyrosine-kinase inhibitor cabozantinib.

Authors:  Rena C Zuo; Andrea B Apolo; John J DiGiovanna; Howard L Parnes; Corrine M Keen; Swati Nanda; William L Dahut; Edward W Cowen
Journal:  JAMA Dermatol       Date:  2015-02       Impact factor: 10.282

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.